News
We provide the latest news from the world of economics and finance
We provide the latest news from the world of economics and finance
(RTTNews) - Immunome, Inc. (IMNM), a biotechnology company, announced that it has priced public offering of 10 million shares of common stock at $20.00 per share. The company expects offering to close on February 16, 2024.
Immunome expects offering gross proceeds, before deducting underwriting discounts and commissions and offering expenses, to be $200.0 million.
In addition, Immunome granted underwriters a 30-day option to buy additional 1.5 million common shares at public offering price, less underwriting discounts and commissions.
J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@just2trade.online
